Literature DB >> 19902169

[What comes after docetaxel?].

C-H Ohlmann1, M Stöckle.   

Abstract

Chemotherapy with docetaxel represents the standard first-line treatment in patients with castration-resistant prostate cancer (CRPC). In cases of progression after treatment with docetaxel no standard treatment recommendation exists since no treatment was able to show a survival benefit in clinical trials. This review focuses on available treatment options for patients with progressive CRPC and highlights promising treatments that are currently under investigation in clinical trials including abiraterone acetate and MDV3100.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 19902169     DOI： 10.1007/s00120-009-2146-6

Source DB:  PubMed          Journal:  Urologe A        ISSN： 0340-2592            Impact factor:   0.639


  26 in total

1.  A phase II trial of imatinib mesylate in patients with biochemical relapse of prostate cancer after definitive local therapy.

Authors:  Amy M Lin; Brian I Rini; Vivian Weinberg; Kristen Fong; Charles J Ryan; Jonathan E Rosenberg; Lawrence Fong; Eric J Small
Journal:  BJU Int       Date:  2006-10       Impact factor: 5.588

2.  Bone marrow aspiration for disseminated tumor cell detection: a must-have test or is the jury still out?

Authors:  Howard I Scher; Klaus Pantel
Journal:  J Clin Oncol       Date:  2009-02-23       Impact factor: 44.544

3.  Randomized phase II study of two doses of gefitinib in hormone-refractory prostate cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group.

Authors:  C M Canil; M J Moore; E Winquist; T Baetz; M Pollak; K N Chi; S Berry; D S Ernst; L Douglas; M Brundage; B Fisher; A McKenna; L Seymour
Journal:  J Clin Oncol       Date:  2005-01-20       Impact factor: 44.544

4.  [Feasibility of targeted therapy based on immunohistochemical expression analysis in androgen-independent prostate cancer].

Authors:  C-H Ohlmann; E Markert; M Gerharz; D Pfister; H-P Dienes; U Engelmann; A Heidenreich
Journal:  Urologe A       Date:  2008-09       Impact factor: 0.639

5.  Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.

Authors:  Ian F Tannock; Ronald de Wit; William R Berry; Jozsef Horti; Anna Pluzanska; Kim N Chi; Stephane Oudard; Christine Théodore; Nicholas D James; Ingela Turesson; Mark A Rosenthal; Mario A Eisenberger
Journal:  N Engl J Med       Date:  2004-10-07       Impact factor: 91.245

6.  [Dutasteride in the treatment of hormone refractory prostate cancer].

Authors:  F Arena
Journal:  Minerva Urol Nefrol       Date:  2008-06       Impact factor: 3.720

7.  Results from a monocentric phase II trial of erlotinib in patients with metastatic prostate cancer.

Authors:  G Gravis; F Bladou; N Salem; A Gonçalves; B Esterni; J Walz; S Bagattini; M Marcy; S Brunelle; P Viens
Journal:  Ann Oncol       Date:  2008-05-07       Impact factor: 32.976

Review 8.  Taxane refractory prostate cancer.

Authors:  Paul Mathew; Robert Dipaola
Journal:  J Urol       Date:  2007-07-20       Impact factor: 7.450

9.  Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study.

Authors:  Dominik R Berthold; Gregory R Pond; Freidele Soban; Ronald de Wit; Mario Eisenberger; Ian F Tannock
Journal:  J Clin Oncol       Date:  2008-01-10       Impact factor: 44.544

10.  A clinical phase II study with sorafenib in patients with progressive hormone-refractory prostate cancer: a study of the CESAR Central European Society for Anticancer Drug Research-EWIV.

Authors:  S Steinbild; K Mross; A Frost; R Morant; S Gillessen; C Dittrich; D Strumberg; A Hochhaus; A-R Hanauske; L Edler; I Burkholder; M Scheulen
Journal:  Br J Cancer       Date:  2007-11-27       Impact factor: 7.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.